Investig Clin Urol.  2020 Feb;61(Suppl 1):S3-S7. 10.4111/icu.2020.61.S1.S3.

The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer

Affiliations
  • 1Department of Urology, University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, OK, USA. Michael-Cookson@ouhsc.edu

Abstract

Metastatic prostate cancer is a heterogeneous disease entity. Men without prior androgen deprivation therapy exposure are termed metastatic castration sensitive prostate cancer (mCSPC). The goal of this article is to update the reader on the rapidly changing landscape of treatment for men with mCSPC. Along with the options available to the clinician for treatment of men with mCSPC, the care of these patients has evolved into a multi-disciplinary field with expanding roles for medical, urologic, and radiation oncologists.

Keyword

Classification; Disease management; Drug therapy; Prostatic neoplasms; Therapeutics

MeSH Terms

Castration*
Classification
Disease Management
Drug Therapy
Humans
Male
Prostate*
Prostatic Neoplasms*
Full Text Links
  • ICU
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error